Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and spe… Read more
Market Cap & Net Worth: Hikma Pharmaceuticals PLC (HKMPF)
Hikma Pharmaceuticals PLC (PINK:HKMPF) has a market capitalization of $5.80 Billion ($5.80 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #3249 globally and #2163 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hikma Pharmaceuticals PLC's stock price $26.20 by its total outstanding shares 221451926 (221.45 Million).
Hikma Pharmaceuticals PLC Market Cap History: 2015 to 2025
Hikma Pharmaceuticals PLC's market capitalization history from 2015 to 2025. Data shows growth from $6.12 Billion to $5.80 Billion (0.55% CAGR).
Hikma Pharmaceuticals PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hikma Pharmaceuticals PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.73x
Hikma Pharmaceuticals PLC's market cap is 1.73 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
15.09x
Hikma Pharmaceuticals PLC's market cap is 15.09 times its annual earnings
10.35x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $6.12 Billion | $1.44 Billion | $252.00 Million | 4.25x | 24.28x |
| 2016 | $4.17 Billion | $1.95 Billion | $155.00 Million | 2.14x | 26.94x |
| 2017 | $2.87 Billion | $1.94 Billion | -$843.00 Million | 1.48x | N/A |
| 2018 | $4.07 Billion | $2.07 Billion | $282.00 Million | 1.97x | 14.43x |
| 2019 | $5.09 Billion | $2.21 Billion | $486.00 Million | 2.31x | 10.48x |
| 2020 | $6.91 Billion | $2.34 Billion | $431.00 Million | 2.95x | 16.03x |
| 2021 | $5.85 Billion | $2.55 Billion | $421.00 Million | 2.29x | 13.89x |
| 2022 | $3.95 Billion | $2.52 Billion | $188.00 Million | 1.57x | 20.98x |
| 2023 | $4.89 Billion | $2.88 Billion | $190.00 Million | 1.70x | 25.72x |
| 2024 | $5.42 Billion | $3.13 Billion | $359.00 Million | 1.73x | 15.09x |
Competitor Companies of HKMPF by Market Capitalization
Companies near Hikma Pharmaceuticals PLC in the global market cap rankings as of March 18, 2026.
Key companies related to Hikma Pharmaceuticals PLC by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Hikma Pharmaceuticals PLC Historical Marketcap From 2015 to 2025
Between 2015 and today, Hikma Pharmaceuticals PLC's market cap moved from $6.12 Billion to $ 5.80 Billion, with a yearly change of 0.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $5.80 Billion | +7.05% |
| 2024 | $5.42 Billion | +10.88% |
| 2023 | $4.89 Billion | +23.88% |
| 2022 | $3.95 Billion | -32.55% |
| 2021 | $5.85 Billion | -15.35% |
| 2020 | $6.91 Billion | +35.65% |
| 2019 | $5.09 Billion | +25.15% |
| 2018 | $4.07 Billion | +41.73% |
| 2017 | $2.87 Billion | -31.22% |
| 2016 | $4.17 Billion | -31.77% |
| 2015 | $6.12 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Hikma Pharmaceuticals PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.80 Billion USD |
| MoneyControl | $5.80 Billion USD |
| MarketWatch | $5.80 Billion USD |
| marketcap.company | $5.80 Billion USD |
| Reuters | $5.80 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.